Rockefeller Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Rockefeller Capital Management’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$251K	Buy	6,112 +3,016	+97%	+$109K	﹤0.01%	2480
2026 Q1	$94.4K	Buy	3,096 +1,810	+141%	+$59.8K	﹤0.01%	2911
2025 Q4	$46.1K	Buy	1,286 +1,076	+512%	+$32.9K	﹤0.01%	3114
2025 Q3	$5.06K	Buy	+210	New	+$4.39K	﹤0.01%	3871
2025 Q2	–	Sell	-50,210	Closed	-$479K	–	1757
2025 Q1	$479K	Buy	50,210 +210	+0.4%	+$2.21K	﹤0.01%	1493
2024 Q4	$622K	Hold	50,000	–	–	﹤0.01%	1410
2024 Q3	$488K	Buy	50,000 +20,000	+67%	+$234K	﹤0.01%	1437
2024 Q2	$484K	Sell	30,000 -30,000	-50%	-$541K	﹤0.01%	1440
2024 Q1	$1.29M	Hold	60,000	–	–	﹤0.01%	1172
2023 Q4	$916K	Buy	+60,000	New	+$1.07M	﹤0.01%	1171

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's INDV Position: Q2 2026 in Review

Rockefeller Capital Management increased its Indivior Pharmaceuticals (INDV) stake by 97% in Q2 2026, buying an estimated $109K and bringing the position to 6,112 shares worth $251K. The position accounts for ﹤0.01% of the portfolio, ranked #2480.

Rockefeller Capital Management first reported a position in INDV in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.29M in Q1 2024. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Rockefeller Capital Management held 6,112 shares of Indivior Pharmaceuticals worth $251K as of Q2 2026.
Rockefeller Capital Management bought 3,016 Indivior Pharmaceuticals shares in Q2 2026, an estimated $109K.
Indivior Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2480 holding.
Rockefeller Capital Management first reported a position in Indivior Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Rockefeller Capital Management's Indivior Pharmaceuticals position peaked at $1.29M in Q1 2024.
338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.